Skip to main content
Ethical considerations in the treatment of multiple sclerosis fatigue.
Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion.
Dare we mention the C-word?
Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
Is multiple sclerosis a risk factor for infections?
The future of microbiome research in neuroinflammatory disorders.
The COVID-19 pandemic and the use of MS disease-modifying therapies.
Big pharma and social responsibility.
Ageing and multiple sclerosis.